Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7503884 | 1.00 | PHGDH (0.42) | PHGDHMGLLSLC18A3MEN1KMT2A | |
| SCHEMBL42786 | 1.00 | PHGDH (0.42) | PHGDHMGLLSLC18A3MEN1KMT2A | |
| SCHEMBL42221 | 0.97 | PHGDH (0.39) | PHGDHMGLLSLC18A3MEN1KMT2A | |
| SCHEMBL9432067 | 0.93 | PHGDH (0.38) | PHGDHMGLLSLC18A3MEN1KMT2A | |
| SCHEMBL193442 | 0.92 | PHGDH (0.34) | PHGDHMGLLSLC18A3MEN1KMT2A | |
| SCHEMBL188355 | 0.86 | — | — | |
| SCHEMBL337764 | 0.85 | L3MBTL1 (0.34) | PHGDHMGLLSLC18A3HTR6ALDH1A1 | |
| SCHEMBL1447602 | 0.85 | L3MBTL1 (0.34) | PHGDHMGLLSLC18A3MEN1KMT2A | |
| SCHEMBL597739 | 0.82 | L3MBTL1 (0.35) | MEN1KMT2AHTR6OPRL1HRH3 | |
| SCHEMBL4166916 | 0.81 | HTR6 (0.41) | PHGDHMGLLSLC18A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3564232-B1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2022-01-26 | — | — | EP | claimed |
| US-10954216-B2 | BMP-signal-inhibiting compound | RIKEN (JP) | 2021-03-23 | — | — | US | claimed |
| US-20210040326-A1 | AZACYANINE DYES AND USE THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-02-11 | — | — | US | claimed |
| EP-3768780-A1 | AZACYANINE DYES AND USE THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-01-27 | — | — | EP | claimed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2019-11-07 | — | — | US | claimed |
| US-20190292371-A1 | AZACYANINE DYES AND USE THEREOF | INTRACE MEDICAL SA (CH) | 2019-09-26 | — | — | US | claimed |
| WO-1999002163-A1 | INHIBITORS OF NEUTROPHIL MEDIATED OXIDANT PRODUCTION | ELI LILLY AND COMPANY (US) | 1999-01-21 | — | — | WO | claimed |
| US-5773441-A | PRODRUGS; ANIMAL HUSBANDRY | ELI LILLY AND COMPANY (US) | 1998-06-30 | — | — | US | claimed |
| EP-0819005-A1 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-01-21 | — | — | EP | claimed |
| EP-0781277-A1 | NEUROKININ ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 1997-07-02 | — | — | EP | claimed |
| EP-0761220-A1 | 2-Acylaminopropanamides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1997-03-12 | — | — | EP | claimed |
| WO-1997006803-A1 | 2-ACYLAMINOPROPANAMIDES AS GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1997-02-27 | — | — | WO | claimed |
| US-5565568-A | USEFUL IN TREATMENT OR PREVENTION OF A PHYSIOLOGICAL DISORDER ASSOCIATED WITH AN EXCESS OF TACHYKININS | ELI LILLY AND COMPANY (US) | 1996-10-15 | — | — | US | claimed |
| WO-1996031214-A1 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-10-10 | — | — | WO | claimed |
| EP-0714891-A1 | Heterocyclic tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-06-05 | — | — | EP | claimed |
| WO-1996008480-A1 | NEUROKININ ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 1996-03-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | PHGDH 921/4885MGLL 773/4885SLC18A3 1283/4885 |
| US-10954216-B2 | BMP-signal-inhibiting compound | BMP1, BMP2, BMP4 | PHGDH 981/4885MGLL 4645/4885SLC18A3 4845/4885 |
| US-20210040326-A1 | AZACYANINE DYES AND USE THEREOF | INMT, AZI2, MYADM | PHGDH 3746/4885MGLL 4461/4885SLC18A3 341/4885 |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | BMP1, BMP2, BMPR2 | PHGDH 1043/4885MGLL 4345/4885SLC18A3 4848/4885 |
| US-20190292371-A1 | AZACYANINE DYES AND USE THEREOF | INMT, AZI2, MYADM | PHGDH 3746/4885MGLL 4461/4885SLC18A3 341/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | PHGDH 3151/4885MGLL 2250/4885SLC18A3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.